TR201200212A2 - Risedronat içeren geliştirilmiş formülasyonlar. - Google Patents

Risedronat içeren geliştirilmiş formülasyonlar.

Info

Publication number
TR201200212A2
TR201200212A2 TR2012/00212A TR201200212A TR201200212A2 TR 201200212 A2 TR201200212 A2 TR 201200212A2 TR 2012/00212 A TR2012/00212 A TR 2012/00212A TR 201200212 A TR201200212 A TR 201200212A TR 201200212 A2 TR201200212 A2 TR 201200212A2
Authority
TR
Turkey
Prior art keywords
formulations containing
containing risedronate
enhanced formulations
risedronate
enhanced
Prior art date
Application number
TR2012/00212A
Other languages
English (en)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2012/00212A priority Critical patent/TR201200212A2/tr
Publication of TR201200212A2 publication Critical patent/TR201200212A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Packages (AREA)

Abstract

Mevcut buluş kemik erimesi ve ilişkili hastalıkların önlenmesinde ve tedavisinde kullanılacak risedronat içeren farmasötik formülasyonlara ilişkindir.@
TR2012/00212A 2011-01-06 2012-01-06 Risedronat içeren geliştirilmiş formülasyonlar. TR201200212A2 (tr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TR2012/00212A TR201200212A2 (tr) 2011-01-06 2012-01-06 Risedronat içeren geliştirilmiş formülasyonlar.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2011/00149A TR201100149A2 (tr) 2011-01-06 2011-01-06 Geliştirilmiş risedronat formülasyonu.
TR2012/00212A TR201200212A2 (tr) 2011-01-06 2012-01-06 Risedronat içeren geliştirilmiş formülasyonlar.

Publications (1)

Publication Number Publication Date
TR201200212A2 true TR201200212A2 (tr) 2012-07-23

Family

ID=45787321

Family Applications (4)

Application Number Title Priority Date Filing Date
TR2011/00149A TR201100149A2 (tr) 2011-01-06 2011-01-06 Geliştirilmiş risedronat formülasyonu.
TR2012/00213A TR201200213A2 (tr) 2011-01-06 2012-01-06 Kombine dozaj formları.
TR2012/00212A TR201200212A2 (tr) 2011-01-06 2012-01-06 Risedronat içeren geliştirilmiş formülasyonlar.
TR2012/00211A TR201200211A2 (tr) 2011-01-06 2012-01-06 Risedronat içeren farmasötik granüller.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
TR2011/00149A TR201100149A2 (tr) 2011-01-06 2011-01-06 Geliştirilmiş risedronat formülasyonu.
TR2012/00213A TR201200213A2 (tr) 2011-01-06 2012-01-06 Kombine dozaj formları.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2012/00211A TR201200211A2 (tr) 2011-01-06 2012-01-06 Risedronat içeren farmasötik granüller.

Country Status (3)

Country Link
EP (1) EP2661258B1 (tr)
TR (4) TR201100149A2 (tr)
WO (1) WO2012093980A1 (tr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77243A (en) 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
TR200900878A2 (tr) * 2009-02-05 2010-08-23 Bi̇lgi̇ç Mahmut Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar

Also Published As

Publication number Publication date
TR201200211A2 (tr) 2012-07-23
TR201100149A2 (tr) 2012-07-23
TR201200213A2 (tr) 2012-07-23
WO2012093980A1 (en) 2012-07-12
EP2661258B1 (en) 2016-04-27
EP2661258A1 (en) 2013-11-13

Similar Documents

Publication Publication Date Title
IN2014MN00948A (tr)
EA201590165A1 (ru) Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
TN2015000278A1 (en) Autotaxin inhibitors
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
UA115231C2 (uk) Сполуки імідазопіролідинонів
IN2012DN06720A (tr)
IN2014MN00987A (tr)
IN2014MN02069A (tr)
EA201991484A1 (ru) Лекарственные формы энзалутамида
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
IN2014MN00986A (tr)
IN2014MN02049A (tr)
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201201296A1 (ru) Способы лечения диабетических язв стопы
NZ702253A (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
EA201270728A1 (ru) Пуриновые соединения
TR201004464A2 (tr) Kemik erimesi için formülasyon.
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
PH12014502065A1 (en) Vesicular formulations